Castleark Management LLC grew its position in Iqvia Holdings Inc (NYSE:IQV) by 9.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 239,194 shares of the medical research company’s stock after acquiring an additional 21,189 shares during the quarter. Iqvia comprises approximately 1.5% of Castleark Management LLC’s portfolio, making the stock its 8th biggest position. Castleark Management LLC owned approximately 0.12% of Iqvia worth $38,486,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Investec Asset Management LTD purchased a new position in Iqvia during the 2nd quarter worth $340,389,000. Egerton Capital UK LLP acquired a new stake in Iqvia in the second quarter valued at about $224,093,000. BlackRock Inc. lifted its position in Iqvia by 12.0% in the first quarter. BlackRock Inc. now owns 12,290,692 shares of the medical research company’s stock valued at $1,768,016,000 after purchasing an additional 1,313,508 shares during the period. FMR LLC lifted its position in Iqvia by 27.5% in the first quarter. FMR LLC now owns 5,376,239 shares of the medical research company’s stock valued at $773,372,000 after purchasing an additional 1,158,248 shares during the period. Finally, Janus Henderson Group PLC boosted its holdings in Iqvia by 19.3% in the 2nd quarter. Janus Henderson Group PLC now owns 3,630,639 shares of the medical research company’s stock valued at $584,166,000 after purchasing an additional 588,179 shares in the last quarter. 89.93% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Kevin C. Knightly sold 6,945 shares of Iqvia stock in a transaction that occurred on Monday, July 29th. The stock was sold at an average price of $158.53, for a total transaction of $1,100,990.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 96,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 19th. The shares were sold at an average price of $150.00, for a total value of $14,400,000.00. The disclosure for this sale can be found here. Insiders sold 2,819,251 shares of company stock worth $441,863,046 over the last quarter. Company insiders own 6.00% of the company’s stock.

A number of equities analysts have recently issued reports on the company. Barclays set a $180.00 target price on Iqvia and gave the stock a “buy” rating in a research note on Monday, July 15th. Svb Leerink initiated coverage on Iqvia in a research note on Tuesday, May 28th. They issued an “outperform” rating and a $160.00 price target on the stock. Credit Suisse Group lifted their price target on Iqvia from $165.00 to $170.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. William Blair reaffirmed an “outperform” rating on shares of Iqvia in a report on Wednesday, June 19th. Finally, Wells Fargo & Co increased their price objective on Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $162.08.

IQV stock traded down $0.28 during midday trading on Wednesday, hitting $150.13. 236,580 shares of the stock were exchanged, compared to its average volume of 937,382. The stock’s 50-day moving average price is $155.65 and its 200-day moving average price is $146.47. The stock has a market cap of $29.75 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 1.85 and a beta of 0.90. Iqvia Holdings Inc has a fifty-two week low of $104.90 and a fifty-two week high of $164.13. The company has a debt-to-equity ratio of 1.72, a quick ratio of 1.14 and a current ratio of 1.14.

Iqvia (NYSE:IQV) last posted its earnings results on Wednesday, July 24th. The medical research company reported $1.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.38 by $0.01. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. Iqvia had a return on equity of 15.95% and a net margin of 2.31%. Iqvia’s revenue was up 6.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.29 earnings per share. Research analysts anticipate that Iqvia Holdings Inc will post 5.87 EPS for the current year.

Iqvia Company Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What are the risks of holding treasury bonds?

Institutional Ownership by Quarter for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with's FREE daily email newsletter.